ResultsIQ

ResultsIQ › Latest results › Neuland Laboratories Limited

Neuland Laboratories Limited Q4 FY25 results deck summary

NSE: NEULANDLAB · BSE: 524558

Results deck of 15 May 2025, summarised by AI from the filing.

Neuland FY25 Total Income ₹1,497.3 cr (-4.7% YoY) and PAT ₹259.4 cr (-13.4% YoY); management expects growth to resume in FY26.

Key takeaways

  1. Q4FY25 results Total Income ₹335.8 cr (-14.0% YoY), EBITDA ₹58.2 cr (-48.1% YoY), PAT ₹27.7 cr (-59.0% YoY)
  2. FY26 outlook Management expects growth trajectory to resume in FY26
  3. Net debt change Net Debt stood at ₹(228.7) cr as at Q4FY25 end compared to ₹(32.6) cr as at Q4FY24 end
  4. CMS growth driver CMS revenues of ₹637 cr driven by commercial molecules; increasing interest from biotechs leading to more early-stage projects
  5. Margin decline FY25 EBITDA margin decreased by 730 bps YoY to 22.9%

Original filing on BSE

Neuland Laboratories Limited Q1 FY27 results

As filed: Revenue ₹642 cr (+119% year on year), EBITDA ₹223 cr (+300% year on year), PAT ₹148 cr (+300% year on year), EBITDA margin 34.7% (+1,000 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹776 cr (+137% year on year), EBITDA ₹307 cr (+300% year on year), PAT ₹213 cr (+300% year on year), EBITDA margin 39.6% (+1,000 bps). Score 100 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −0.2% in 30 days (Nifty 500: −0.8%).
  • Q3 FY26: Revenue ₹440 cr (+10% year on year), EBITDA ₹77.1 cr (−10% year on year), PAT ₹40.6 cr (−60% year on year), EBITDA margin 17.5% (−406 bps). Score 44 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was below it. EBITDA margin fell 406 bps year on year. Revenue fell 14% from last quarter. Share price after the results: −7.6% in 30 days (Nifty 500: −6.9%).
  • Q2 FY26: Revenue ₹514 cr (+65% year on year), EBITDA ₹155 cr (+150% year on year), PAT ₹97.0 cr (+194% year on year), EBITDA margin 30.2% (+1,000 bps). Score 100 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −5.3% in 28 days (Nifty 500: +1.3%).
  • Q1 FY26: Revenue ₹293 cr (−33% year on year), EBITDA ₹35.0 cr (−72% year on year), PAT ₹14.0 cr (−86% year on year), EBITDA margin 12.0% (−1,000 bps). Score 15 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 1000 bps year on year. Other income 44% of PBT. Revenue fell 11% from last quarter. Share price after the results: +1.3% in 29 days (Nifty 500: −2.0%).
  • Q4 FY25: Revenue ₹328 cr (−15% year on year), EBITDA ₹51.0 cr (−52% year on year), PAT ₹28.0 cr (−59% year on year), EBITDA margin 15.6% (−1,000 bps). Score 28 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend; profit growth was well below it. EBITDA margin fell 1000 bps year on year. Revenue fell 18% from last quarter. Share price after the results: +11.2% in 29 days (Nifty 500: +0.5%).
  • Q3 FY25: Revenue ₹398 cr (+1% year on year), EBITDA ₹86.0 cr (−29% year on year), PAT ₹102 cr (−31% year on year), EBITDA margin 21.6% (−918 bps). Score 36 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit before exceptional items growth were below it. EBITDA margin fell 918 bps year on year.
  • Q2 FY25: Revenue ₹311 cr (−26% year on year), EBITDA ₹62.0 cr (−55% year on year), PAT ₹33.0 cr (−63% year on year), EBITDA margin 19.9% (−1,000 bps). Score 0 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 29% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Neuland Laboratories Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.